LUND, Sweden, April 26, 2023 /PRNewswire/ -- Immunovia (Nasdaq
Stockholm: IMMNOV), the diagnostics company that has launched the
world's first test dedicated to the early detection of pancreatic
cancer, today announced it will host an event to discuss the
adoption of IMMrayTM PanCan-d test key opinion
leaders on May 3, 2023, at
16:00 pm CET (10:00 am ET).
The event will feature two panel discussions with key opinion
leaders:
David Bakelman
CEO
National Pancreas Foundation
Cheryl Meguid, DNP
Director of the Pancreatic Cancer High Risk Screening Clinic
Regional Medical Director of Oncology Multidisciplinary
Programs
Multidisciplinary Clinic Coordinator for Pancreas and Biliary
Disease
University of Colorado Anschutz
Medical Campus
Rosario Ligresti, MD,
FASGE
Division Chief, Gastroenterology
Academic Director of Gastroenterology
Hackensack University Medical Center
Immunovia Management will also discuss its commercialization
strategy for IMMrayTM PanCan-d test in the U.S.
For more information and to register for the webcast please
click here.
For more information, please contact:
Philipp Mathieu,
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Cheif Financial Officer
karin.almqvist.liwendahl@immunovia.com
+46 709 11 56 08
About Immunovia
Immunovia is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer
groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated, addressable market size of 1.8 million individuals per
year who could benefit from our test.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
The following files are available for download:
https://mb.cision.com/Main/13121/3758873/2014431.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-to-discuss-adoption-of-immray-pancan-d-with-key-opinion-leaders-on-may-3-2023-301808229.html